These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35077669)

  • 1. Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression.
    Zagare A; Barmpa K; Smajic S; Smits LM; Grzyb K; Grünewald A; Skupin A; Nickels SL; Schwamborn JC
    Am J Hum Genet; 2022 Feb; 109(2):311-327. PubMed ID: 35077669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids.
    Kim H; Park HJ; Choi H; Chang Y; Park H; Shin J; Kim J; Lengner CJ; Lee YK; Kim J
    Stem Cell Reports; 2019 Mar; 12(3):518-531. PubMed ID: 30799274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
    Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
    Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
    Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
    Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.
    Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of
    Sadhukhan D; Biswas A; Bhaduri A; Sarkar N; Biswas A; Das SK; Banerjee TK; Ray K; Ray J
    Indian J Med Res; 2020 Jun; 151(6):592-597. PubMed ID: 32719233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinson's disease-linked
    Wulansari N; Darsono WHW; Woo HJ; Chang MY; Kim J; Bae EJ; Sun W; Lee JH; Cho IJ; Shin H; Lee SJ; Lee SH
    Sci Adv; 2021 Feb; 7(8):. PubMed ID: 33597231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
    Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes.
    Booth HDE; Wessely F; Connor-Robson N; Rinaldi F; Vowles J; Browne C; Evetts SG; Hu MT; Cowley SA; Webber C; Wade-Martins R
    Neurobiol Dis; 2019 Sep; 129():56-66. PubMed ID: 31085228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality.
    Walter J; Bolognin S; Antony PMA; Nickels SL; Poovathingal SK; Salamanca L; Magni S; Perfeito R; Hoel F; Qing X; Jarazo J; Arias-Fuenzalida J; Ignac T; Monzel AS; Gonzalez-Cano L; Pereira de Almeida L; Skupin A; Tronstad KJ; Schwamborn JC
    Stem Cell Reports; 2019 May; 12(5):878-889. PubMed ID: 30982740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Targets from LRRK2 Rescue Phenotypes.
    Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression.
    Zhu Y; Wang C; Yu M; Cui J; Liu L; Xu Z
    Protein Cell; 2013 Sep; 4(9):711-21. PubMed ID: 27023913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.